Submissions for variant NM_000478.6(ALPL):c.815G>A (p.Arg272His)

gnomAD frequency: 0.00002  dbSNP: rs781272386

Total submissions: 7

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV000587658	SCV000696803	likely pathogenic	Hypophosphatasia	2017-07-12	criteria provided, single submitter	clinical testing	Variant summary: The ALPL c.815G>A (p.Arg272His) variant (alternatively also known as R255H) involves the alteration of a conserved nucleotide, resulting in a missense change residing in the alkaline-phosphatase-like core domain (InterPro). 3/3 in silico tools predict damaging outcome for this variant. This variant was found in the large control database ExAC at a frequency of 0.0000083 (1/120878 control chromosomes), which does not exceed the estimated maximal expected allele frequency of a pathogenic ALPL variant (0.0035355). The variant has been identified in a homozgous patient with hypophosphatasia (HPP), with in vitro functional studies showing that residual enzyme activity is < 10% of WT levels (Brun-Heath_MGM_2005). In addition, molecular modeling suggests the variant lies within a conserved calcium-binding domain, which is supported by the fact that several variants at the same codon are found in HPP patients (R272C, R272L), suggesting the residue is critical for protein function. The variant has not been classified in reputable databases or by clinical diagnostics laboratories. Taken together, this variant is classified as likely pathogenic until additional HPP patients with the variant are identified.
GeneDx	RCV001597180	SCV001830764	pathogenic	not provided	2020-03-02	criteria provided, single submitter	clinical testing	Published functional studies demonstrate a damaging effect (Brun-Heath et al., 2005); Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 32160374, 29236161, 28663156, 19500388, 15694177)
Invitae	RCV001597180	SCV002236321	pathogenic	not provided	2023-09-21	criteria provided, single submitter	clinical testing	For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Arg272 amino acid residue in ALPL. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 17253930, 18559907, 24276437, 24378058). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 272 of the ALPL protein (p.Arg272His). This variant is present in population databases (rs781272386, gnomAD 0.003%). This missense change has been observed in individual(s) with clinical features of autosomal dominant and recessive ALPL-related conditions (PMID: 15694177, 28663156, 29236161). This variant is also known as R255H. ClinVar contains an entry for this variant (Variation ID: 495882). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ALPL protein function. Experimental studies have shown that this missense change affects ALPL function (PMID: 15694177).
Genome Diagnostics Laboratory, The Hospital for Sick Children	RCV002279370	SCV002564839	pathogenic	Osteogenesis imperfecta	2022-06-14	criteria provided, single submitter	clinical testing
Baylor Genetics	RCV003459459	SCV004190603	pathogenic	Adult hypophosphatasia	2023-06-06	criteria provided, single submitter	clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories	RCV001597180	SCV004564362	pathogenic	not provided	2023-02-24	criteria provided, single submitter	clinical testing	The ALPL c.815G>A; p.Arg272His variant (rs781272386), also known as R255H, is reported in the literature in individuals affected with autosomal dominant and recessive hypophosphatasia (Brun-Heath 2005, Saglam 2017, Taillandier 2018). This variant is also reported in ClinVar (Variation ID: 495882) and is found in the non-Finnish European population with an allele frequency of 0.003% (4/129072 alleles) in the Genome Aggregation Database. Additionally, other variants at this codon (c.814C>T, p.Arg272Cys; c.815G>T, p.Arg272Leu) have been reported in individuals with ALPL- related conditions and are considered pathogenic (Del Angel 2020, Zhang 2021). Functional analyses of the variant protein show reduced enzyme activity (Brun-Heath 2005, Del Angel 2020). Computational analyses predict that this variant is deleterious (REVEL: 0.896). Based on available information, this variant is considered to be pathogenic. References: Brun-Heath I et al. Characterization of 11 novel mutations in the tissue non-specific alkaline phosphatase gene responsible for hypophosphatasia and genotype-phenotype correlations. Mol Genet Metab. 2005 Mar;84(3):273-7. PMID: 15694177. Del Angel G et al. Large-scale in vitro functional testing and novel variant scoring via protein modeling provide insights into alkaline phosphatase activity in hypophosphatasia. Hum Mutat. 2020 Jul;41(7):1250-1262. PMID: 32160374. Saglam H et al. Clinical and Genetic Findings of Turkish Hypophosphatasia Cases. J Clin Res Pediatr Endocrinol. 2017 Sep 1;9(3):229-236. PMID: 28663156. Taillandier A et al. Genetic analysis of adults heterozygous for ALPL mutations. J Bone Miner Metab. 2018 Nov;36(6):723-733. PMID: 29236161. Zhang L et al. Molecular diagnosis for 55 fetuses with skeletal dysplasias by whole-exome sequencing: A retrospective cohort study. Clin Genet. 2021 Aug;100(2):219-226. PMID: 33942288.
Counsyl	RCV000674432	SCV000799768	likely pathogenic	Infantile hypophosphatasia	2018-05-09	no assertion criteria provided	clinical testing